Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2025-11-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
内部审计制度
Audit Report / Information Classification · 95% confidence The document is titled '内部审计制度' (Internal Audit System) and details the internal audit policies, responsibilities, procedures, and organizational structure of the company 广州市香雪制药股份有限公司. It references relevant laws and regulations, outlines the duties of the internal audit department, audit committee, and audit personnel, and describes the internal control evaluation and reporting process. There are no financial statements, earnings data, or investor presentation content. The document is a formal internal governance and procedural document related to audit practices rather than a report of audit results or financial performance. It is not an announcement or a brief notice but a comprehensive internal policy document. This fits best under Audit Report / Information (AR), which includes applied accounting principles and internal audit information, excluding full annual reports. The document is not a regulatory filing or a report publication announcement since it contains substantive content rather than a brief notice. Therefore, the classification is AR with high confidence. FY 2025
2025-11-28 Chinese
内幕信息管理制度
Governance Information Classification · 95% confidence The document is titled '内幕信息管理制度' which translates to 'Insider Information Management System' and details the company's policies and procedures for managing insider information, including definitions, responsibilities, registration of insiders, confidentiality obligations, and penalties for violations. It references relevant laws and regulatory requirements but does not contain financial statements, earnings data, or other financial performance information. It is a governance-related document outlining internal rules and compliance practices related to insider information management. Therefore, it fits best under Governance Information (CGR). The document length (6854 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2025-11-28 Chinese
总经理工作细则
Governance Information Classification · 100% confidence The document is titled '总经理工作细则' which translates to 'General Manager Work Rules' or 'General Manager Operating Procedures'. It details the governance structure, roles, responsibilities, appointment and removal procedures, powers, obligations, meeting protocols, reporting requirements, and performance evaluation of the company's general manager and senior management. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no audit information, no capital or financing updates, no legal proceedings, no merger or acquisition activity, and no investor presentation content. The document is a governance-related internal policy document outlining management roles and responsibilities, which fits the category of Governance Information (CGR). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, the best classification is Governance Information (CGR).
2025-11-28 Chinese
董事会提名委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Board Nomination Committee Working Rules' of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details the structure, responsibilities, and procedures of the board nomination committee, including the selection and appointment of directors and senior management. There is no financial data, earnings information, or regulatory filing content. It is a governance-related document outlining internal rules and governance practices of the company. Therefore, it fits best under the category of Governance Information (CGR). The document length is 2369 characters, which is consistent with a detailed governance policy document rather than a brief announcement or report publication.
2025-11-28 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for external guarantees by 广州市香雪制药股份有限公司. It details the company's policies, procedures, responsibilities, risk control, approval processes, and disclosure obligations related to providing guarantees to third parties. There is no indication that this is a financial report, audit, earnings release, or any form of regulatory filing. It is a governance-related document outlining internal rules and procedures for managing external guarantees. Therefore, it fits best under Governance Information (CGR). The document length (6483 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2025-11-28 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is a detailed set of rules and regulations governing the board of directors of 广州市香雪制药股份有限公司 (Guangzhou Xiangxue Pharmaceutical Co., Ltd.). It includes sections on the qualifications, duties, rights, and responsibilities of directors and independent directors, the structure and powers of the board, committees under the board, and the role and qualifications of the board secretary. The content is focused on governance practices, board operations, and internal company rules rather than financial results, audit opinions, or shareholder meeting materials. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. Instead, it fits the description of a Governance Information report, which details the company's internal rules, board structure, and governance practices.
2025-11-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.